GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kane Biotech Inc (TSXV:KNE) » Definitions » Equity-to-Asset

Kane Biotech (TSXV:KNE) Equity-to-Asset : -2.02 (As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Kane Biotech Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Kane Biotech's Total Stockholders Equity for the quarter that ended in Mar. 2024 was C$-11.73 Mil. Kane Biotech's Total Assets for the quarter that ended in Mar. 2024 was C$5.80 Mil. Therefore, Kane Biotech's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was -2.02.

The historical rank and industry rank for Kane Biotech's Equity-to-Asset or its related term are showing as below:

TSXV:KNE' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.02   Med: 0.11   Max: 0.9
Current: -2.02

During the past 13 years, the highest Equity to Asset Ratio of Kane Biotech was 0.90. The lowest was -2.02. And the median was 0.11.

TSXV:KNE's Equity-to-Asset is ranked worse than
94.27% of 1554 companies
in the Biotechnology industry
Industry Median: 0.67 vs TSXV:KNE: -2.02

Kane Biotech Equity-to-Asset Historical Data

The historical data trend for Kane Biotech's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kane Biotech Equity-to-Asset Chart

Kane Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 -0.30 -0.63 -1.16 -1.86

Kane Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.42 -1.54 -1.53 -1.86 -2.02

Competitive Comparison of Kane Biotech's Equity-to-Asset

For the Biotechnology subindustry, Kane Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kane Biotech's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kane Biotech's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Kane Biotech's Equity-to-Asset falls into.



Kane Biotech Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Kane Biotech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-10.558/5.681
=-1.86

Kane Biotech's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=-11.732/5.799
=-2.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kane Biotech  (TSXV:KNE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Kane Biotech Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Kane Biotech's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Kane Biotech (TSXV:KNE) Business Description

Traded in Other Exchanges
Address
290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The Company has a separate operating segment for its Stem Animal Health subsidiary, which operates the animal health business. StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, DermaKB and DermaKB Biofilm are trademarks of the company. The firm is also engaged in the animal health business through its Stem Animal Health subsidiary.
Executives
Philip Renaud Director

Kane Biotech (TSXV:KNE) Headlines

No Headlines